February 28, 2022
Pharma Companies Without Comment on Russian Market Future
Pharma companies didn’t want to comment effects of the sanctions against Russia.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
February 28, 2022
Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investmen
Heidelberg Pharma and Huadong Medicine have entered into a strategic partnership with the signing of an exclusive licensing agreement as…
February 28, 2022
Kapruvia Receives Positive CHMP Opinion for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, have announced that the European Medicines Agency’s (EMA) CHMP has recommended…
February 28, 2022
Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat in Patients with Alzheimer’s Disease
Vivoryon Therapeutics a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group have announced that…
February 25, 2022
Abzena, Alira Health and Oncodesign Team Up to Support Access to Specialist Services
Abzena, a partner research organization for integrated services from discovery through to clinical and commercial manufacturing for biologics and bioconjugates,…
February 25, 2022
Sobi’s HLH Drug Recommended for Approval in China
Sobi has announce that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant to the National Medical Products…
February 25, 2022
Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced that the Committee for Medicinal Products for…
February 25, 2022
Idorsia’s QUVIVIQ (daridorexant) Recommended for Approval in Europe as a New Treatment for Adults with Insomnia Disorder
Idorsia Ltd has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European…
February 24, 2022
Atamyo Therapeutics Reaches Significant Regulatory and Financial Milestones for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9
Additional approval of Clinical Trial Application received from Denmark Danish Medicines Agency (DKMA) Orphan Drug Designation awarded from US FDA…
February 24, 2022
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))…